var data={"title":"Bendamustine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bendamustine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/349210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bendamustine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bendamustine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bendeka;</li>\n      <li>Treanda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15065726\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Treanda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957171\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent;</li>\n      <li>\n        Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5958743\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Treanda liquid solution formulation (45 mg/0.5 mL and 180 mg/2 mL) has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Bendamustine is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL):</b> IV: 100 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (as a single agent) for up to 6 cycles (Knauf 2009; Knauf 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CLL, first-line treatment (off-label dosing):</b> IV: 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (Fischer 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CLL, relapsed/refractory (off-label dosing):</b> IV: 70 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (Fischer 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphoma, indolent B-cell, refractory:</i> 120 mg/m<sup>2</sup> on days 1 and 2 of a 21-day treatment cycle (as a single agent) for up to 8 cycles (Kahl 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphoma, indolent (eg, follicular, marginal zone) and mantle cell; first-line treatment (off-label use):</i> 90 mg/m<sup>2</sup> over 30 to 60 minutes on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (Rummel 2013) <b>or</b> 90 mg/m<sup>2</sup> over 30 minutes on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for 6 to 8 cycles (Flinn 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphoma, follicular, relapsed or refractory (off-label dosing):</i> 90 mg/m<sup>2</sup> over 60 minutes on days 1 and 2 of a 35-day treatment cycle (in combination with bortezomib and rituximab) for 5 cycles (Fowler 2011) <b>or</b> 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle for 6 cycles (in combination with obinutuzumab, then followed by obinutuzumab monotherapy in patients with stable disease, complete response, or partial response after 6 cycles of combination therapy) (Sehn 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphoma, mantle cell, relapsed or refractory (off-label use):</i> 90 mg/m<sup>2</sup> over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for up to 4 cycles (Rummel 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, relapsed or refractory (off-label use):</b> IV: 120 mg/m<sup>2</sup> over 30 minutes on days 1 and 2 of a 28-day treatment cycle for up to 6 cycles (Moskowitz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma, salvage therapy (off-label use):</b> IV: 90 to 100 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle for at least 2 cycles (Knop, 2005) <b>or</b> 75 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 cycles (Lentzsch 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia, refractory (off-label use):</b> IV: 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for 6 cycles (Treon 2011) <b>or</b> 90 mg/m<sup>2</sup> over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for 4 cycles (Rummel 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957380\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957381\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;40 mL/minute (Bendeka) or CrCl &lt;30 mL/minute (Treanda): Use is not recommended (according to the manufacturer's labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Data suggest minor changes in systemic exposure may occur with mild to moderate renal impairment. Based on a pharmacokinetic study (patients receiving 120 mg/m<sup>2</sup> for 2 days every 21 days), only slight differences in bendamustine AUC and C<sub>max</sub> were demonstrated in patients with mild (CrCl &gt;50 to &le;80 mL/minute) and moderate (CrCl &gt;30 to &le;50 mL/minute) renal dysfunction, compared to patients with normal renal function (Owen 2010). In a retrospective study of bendamustine in CLL and NHL patients with renal impairment (CrCl &lt;40 mL/minute) compared to patients with CrCl &ge;40 mL/minute, an increased incidence of grades 3/4 thrombocytopenia was noted in NHL patients with renal impairment and grades 3/4 BUN increases were higher when combining data for CLL and NHL patients, compared to those with CrCl &ge;40 mL/minute. Grade 1 and 2 fatigue, nausea, and alopecia were more common in patients with renal impairment (Nordstrom 2014). Further data regarding the effects of renal impairment on systemic bendamustine exposure is necessary; however, renal impairment would not be expected to have a notable effect on bendamustine exposure due to its short half-life and minimal (~3% as unchanged drug) renal excretion (Darwish 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957382\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild  impairment: Use with caution. However, a pharmacokinetic study showed only slight differences in bendamustine AUC and C<sub>max</sub> in  patients with mild hepatic impairment (defined in the study as total bilirubin 1 to 1.5 times ULN or AST greater than ULN), compared to patients with normal hepatic function (Owen 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate  impairment (AST or ALT 2.5 to 10 times ULN and total bilirubin 1.5 to 3 times ULN): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (total bilirubin &gt;3 times ULN): Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20339757\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957403\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Infusion reactions:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1 or 2: Consider premedication with antihistamines, antipyretics, and corticosteroids in subsequent cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Consider discontinuing treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Skin reaction, severe or progressive:</i> Withhold or discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Treatment delay:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity &ge; grade 4: Delay treatment until resolves (ANC &ge;1000/mm<sup>3</sup>, platelets &ge;75,000/mm<sup>3</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhematologic toxicity &ge; grade 2 (clinically significant): Delay treatment until resolves to &le; grade 1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose modification CLL:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity &ge; grade 3: Reduce dose to 50 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (&ge; grade 3), further reduce dose to 25 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle. May cautiously re-escalate dose in subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhematologic toxicity &ge; grade 3 (clinically significant): Reduce dose to 50 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle with discretion. May cautiously re-escalate dose in subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose modification in NHL:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity grade 4: Reduce dose to 90 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (grade 4), further reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhematologic toxicity &ge; grade 3: Reduce dose to 90 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle with discretion. For recurrent toxicity &ge; grade 3, further reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957484\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bendeka: 100 mg/4 mL (4 mL) [contains polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treanda: 45 mg/0.5 mL (0.5 mL [DSC]); 180 mg/2 mL (2 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treanda: 25 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957169\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50085705\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Treanda liquid solution formulation (45 mg/0.5 mL and 180 mg/2 mL) has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957404\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For chronic lymphocytic leukemia, infuse over 30 minutes (Treanda) or 10 minutes (Bendeka). For non-Hodgkin lymphoma, infuse over 60 minutes (Treanda) or 10 minutes (Bendeka). Administration times for off-label uses/doses vary by protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Bendamustine solution (45 mg/0.5 mL and 180 mg/2 mL [Treanda]) contains N, N-dimethylacetamide, which is incompatible with closed-system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS). After dilution of bendamustine solution (Treanda) into the infusion bag, devices containing polycarbonate or ABS (including infusion sets) may be used.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consider premedication with antihistamines, antipyretics, and corticosteroids for patients with a previous grade 1 or 2 infusion reaction to bendamustine. Bendamustine is associated with a moderate emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses for 20 minutes 4 times daily (Perez Fidalgo 2012). May be managed with sodium thiosulfate in the same manner as mechlorethamine extravasation (Schulmeister 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sodium thiosulfate 1/6 M solution (instructions for mechlorethamine):</i> Inject subcutaneously into extravasation area using 2 mL for each mg of drug suspected to have extravasated (Perez Fidalgo 2012; Polovich 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130899\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (if compatible) closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if compatible and dosage form allows) CSTDs are required during administration (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957173\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia:</b> Treatment of chronic lymphocytic leukemia (CLL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphoma:</b> Treatment of indolent B-cell non-Hodgkin lymphoma (NHL) which has progressed during or within 6 months of rituximab treatment or a rituximab-containing regimen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475187\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hodgkin lymphoma (relapsed or refractory); Multiple myeloma (salvage therapy); Non-Hodgkin lymphoma, indolent (eg, follicular, marginal zone), and mantle cell; first-line treatment; Non-Hodgkin lymphoma, mantle cell (relapsed or refractory); Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957165\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bendamustine may be confused with brentuximab, carmustine, lomustine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the  Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Different formulation issues: Several formulations of bendamustine are available: a liquid solution formulation (45 mg/0.5 mL and 180 mg/2 mL [Treanda] and 100 mg/4 mL [Bendeka]), and a powder for reconstitution (5 mg/mL after reconstitution [Treanda]). Concentrations, storage, and compatibility differ between formulations. Use caution when selecting bendamustine formulation for preparation and administration (ISMP [Smetzer 2015]). Do not mix or combine the formulations.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">A solvent in the 45 mg/0.5 mL and 180 mg/2 mL liquid solution formulation of bendamustine (Treanda), N,N-dimethylacetamide, is incompatible with closed-system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS) used for preparing injectable antineoplastics. The plastic components of these devices may dissolve, resulting in subsequent leakage and potential infusion of dissolved plastic into the patient ISMP ([Smetzer 2015]). Do not use the liquid solution formulation if CSTDs, adapters, and syringes containing polycarbonate or ABS are used prior to dilution in the infusion bag. According to the Treanda manufacturer, after dilution into the infusion bag, devices containing polycarbonate or ABS (including infusion sets) may be used. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957205\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (9% to 57%), headache (21%), dizziness (14%), chills (6% to 14%), insomnia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (8% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (7% to 18%), dehydration (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (20% to 75%), vomiting (16% to 40%), diarrhea (9% to 37%), constipation (29%), anorexia (23%), stomatitis (15%), abdominal pain (13%), decreased appetite (13%), dyspepsia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (68% to 99%; grades 3/4: 47% to 94%), bone marrow depression (grades 3/4: 98%; nadir: in week 3), leukopenia (61% to 94%; grades 3/4: 28% to 56%), decreased hemoglobin (88% to 89%; grades 3/4: 11% to 13%), decreased neutrophils (75% to 86%; grades 3/4: 43% to 60%), thrombocytopenia (77% to 86%; grades 3/4: 11% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (14%), weakness (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4% to 22%), dyspnea (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (24% to 34%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (7%), chest pain (6%), hypotension (6%), exacerbation of hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (8%), depression (6%), pain (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (5% to 6%), hyperhidrosis (5%), night sweats (5%), xeroderma (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (9%), hyperuricemia (7%), hyperglycemia (grades 3/4: 3%), hypocalcemia (grades 3/4: 2%), hyponatremia (grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroesophageal reflux disease (10%), xerostomia (9%), dysgeusia (7%), oral candidiasis (6%), abdominal distention (5%), upper abdominal pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (grades 3/4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (grades 3/4: 3%), increased serum AST (grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (10%), infection (6%), herpes simplex infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site pain (6%), catheter pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (6%), limb pain (5%), ostealgia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (10%), sinusitis (9%), pharyngolaryngeal pain (8%), pneumonia (8%), nasopharyngitis (6% to 7%), nasal congestion (5%), wheezing (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis, skin necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucositis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, atrial fibrillation, bronchogenic carcinoma, bullous rash, cardiac failure, dermatological reaction (toxic), DRESS syndrome, erythema, extravasation injury, hepatitis, hepatotoxicity, injection site reaction (including irritation, pain, phlebitis, pruritus, swelling), myelodysplastic syndrome, myeloid leukemia (acute), myocardial infarction, neutropenic sepsis, palpitations, pancytopenia, pneumonia ( <i>Pneumocystis jirovecii</i>), pneumonitis, pulmonary alveolar hemorrhage (with grade 3 thrombocytopenia), pulmonary fibrosis, reactivation of disease (including, but not limited to hepatitis B, cytomegalovirus, <i>Mycobacterium tuberculosis</i>, herpes zoster), sepsis, septic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957180\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (eg, anaphylactic or anaphylactoid reactions) to bendamustine or any component of the formulation. Bendeka is also contraindicated in patients with hypersensitivity to polyethylene glycol 400, propylene glycol, or monothioglycerol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957181\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Myelosuppression (neutropenia, thrombocytopenia, and anemia) is a common toxicity; may require therapy delay and/or dose reduction; monitor blood counts frequently (nadirs typically occurred in the third week of treatment). Complications due to febrile neutropenia and severe thrombocytopenia have been reported (some fatal). ANC should recover to &ge;1,000/mm<sup>3</sup> and platelets to &ge;75,000/mm<sup>3</sup> prior to cycle initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Serious and fatal dermatologic toxicities, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), bullous exanthema, and rash have been reported. Skin reactions have been reported with monotherapy and in combination with other antineoplastic agents or allopurinol and may be progressive or worsen with continued treatment. The risk for severe skin toxicity is increased with concurrent use of allopurinol and other medications known to cause skin toxicity. Monitor closely for dermatologic toxicity. Withhold or discontinue treatment for severe or progressive skin reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Bendamustine is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Erythema, marked swelling, and pain have been reported with extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicities: Bendamustine is associated with a moderate emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Serious and fatal cases of liver injury have been reported, usually within the first 3 months of treatment initiation. Confounding factors in some patients included combination therapy, progressive disease, and/or hepatitis B reactivation. Monitor liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/infusion reaction: Infusion reactions, which may include chills, fever, pruritus, and rash, are common. Rarely, anaphylactic and anaphylactoid reactions have occurred, particularly with the second or subsequent cycle(s). Patients who experienced grade 3 or higher allergic reactions should not be rechallenged. Consider premedication with antihistamines, antipyretics and corticosteroids for patients with a history of grade 1 or 2 infusion reaction. Discontinue for severe allergic reaction or grade 4 infusion reaction; consider discontinuation with grade 3 infusion reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Has been reported with use; monitor potassium closely in patients with cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Pneumonia, hepatitis, sepsis, and septic shock have been reported. Fatalities due to infection have occurred. Patients with myelosuppression are more susceptible to infection; monitor closely. Reactivation of hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster infection may occur in patients receiving bendamustine. Monitor; may require infection prophylaxis and/or treatment prior to bendamustine administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Malignancies (including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial cancer) and premalignant diseases have been reported in patients who have received bendamustine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (usually occurring in the first treatment cycle) may occur as a consequence of antineoplastic treatment, including treatment with bendamustine. May lead to life-threatening acute renal failure (without intervention); vigorous hydration and prophylactic measures (eg, antihyperuricemic therapy) should be instituted prior to treatment in high-risk patients; monitor closely. <b>Note:</b> Allopurinol may increase the risk for bendamustine skin toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment. A pharmacokinetic study showed only slight differences in bendamustine AUC and C<sub>max</sub> in patients with mild hepatic impairment (defined in the study as total bilirubin 1 to 1.5 &times; ULN or AST &gt; ULN), as compared to patients with normal hepatic function (Owen 2010). Use is not recommended in patients with moderate (AST or ALT 2.5 to 10 &times; ULN and total bilirubin 1.5 to 3 &times; ULN) or severe (total bilirubin &gt;3 &times; ULN) hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild to moderate renal impairment. According to the manufacturer, use is not recommended in patients with CrCl &lt;40 mL/minute (Bendenka) or &lt;30 mL/minute (Treanda). A pharmacokinetic study illustrated only slight differences in bendamustine AUC and C<sub>max</sub> in patients with mild (CrCl &gt;50 to &le;80 mL/minute) and moderate (CrCl &gt;30 to &le;50 mL/minute) renal dysfunction, compared to patients with normal renal function (Owen 2010). A retrospective safety study found higher rates of grades 3 and 4 BUN increases and thrombocytopenia, and grades 1 and 2 fatigue, nausea, and alopecia in patients with renal impairment (CrCl &lt;40 mL/minute) compared to those without renal impairment (Nordstrom 2014); monitor blood counts and renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Closed system transfer device incompatibility: Bendamustine solution (Treanda: 45 mg/0.5 mL and 180 mg/2 mL) contains N,N-dimethylacetamide, which is incompatible with closed-system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS). When used to prepare or transfer the concentrated bendamustine solution into the infusion bag, the plastic components of these devices may dissolve, resulting in subsequent leakage and potential infusion of dissolved plastic into the patient (ISMP [Smetzer 2015]). Do not use the liquid solution formulation if CSTDs, adapters, and syringes containing polycarbonate or ABS are used <b>prior</b> to dilution in the infusion bag. According to the Treanda manufacturer, after dilution into the infusion bag, devices containing polycarbonate or ABS (including infusion sets) may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formulations: Several formulations of bendamustine are available: a liquid solution (45 mg/0.5 mL and 180 mg/2 mL [Treanda] and 100 mg/4 mL [Bendeka]) and a powder for reconstitution (5 mg/mL after reconstitution [Treanda]). Concentrations, storage, and compatibility differ between formulations. Use caution when selecting bendamustine formulation for preparation and administration. Do not mix or combine the formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957266\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957265\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9323&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957175\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. For women and men of reproductive potential, effective contraception should be used during and for 3 months after treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957179\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bendamustine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue bendamustine or discontinue breastfeeding, taking into account the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957481\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (monitored weekly [initially] in clinical trials); serum creatinine; liver function tests (ALT, AST, and total bilirubin; prior to and during treatment); monitor potassium and uric acid levels in patients at risk for tumor lysis syndrome; monitor for infusion reactions anaphylaxis, infection (including reactivations), and dermatologic toxicity; monitor IV site during and after infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957479\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bendamustine is an alkylating agent (nitrogen mustard derivative) with a benzimidazole ring (purine analog) which demonstrates only partial cross-resistance (<i>in vitro</i>) with other alkylating agents. It leads to cell death via single and double strand DNA cross-linking. Bendamustine is active against quiescent and dividing cells. The primary cytotoxic activity is due to bendamustine (as compared to metabolites). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5957371\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~20 to 25 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 94% to 96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (extensive), via CYP1A2 to active (minor) metabolites gamma-hydroxy bendamustine (M3) and N-desmethyl-bendamustine (M4); also via hydrolysis to low cytotoxic metabolites, monohydroxy bendamustine (HP1) and dihydroxy bendamustine (HP2)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Bendamustine: ~40 minutes; M3: ~3 hours; M4: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: At end of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~25%); urine (~50%; ~3% as active parent drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pharmacokinetic note: In a pharmacokinetic study, a 10 minute infusion of Bendeka (120 mg/m<sup>2</sup>) resulted in higher maximum plasma concentrations and equivalent systemic exposure as the same dose of Treanda infused over 60 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321818\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bendeka Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/4 mL (4 mL): $2,910.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Treanda Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $891.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $3,566.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875349\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bemustin (LK);</li>\n      <li>Bendam (AR);</li>\n      <li>Bendamax (BD);</li>\n      <li>Bendavar (CL);</li>\n      <li>Bendinfus (BG);</li>\n      <li>Bendit (IN);</li>\n      <li>Eriotib (AR);</li>\n      <li>Levact (AT, BE, CZ, DK, ES, FI, FR, GB, GR, IE, IS, IT, LU, NL, NO, PL, PT, SI, SK, TR);</li>\n      <li>Mustin (IN);</li>\n      <li>Rhomustin (BG);</li>\n      <li>Ribomustin (AE, AR, CH, CL, CO, CZ, DE, IL, LB, NZ, PE, QA, TH);</li>\n      <li>Ribovact (SE);</li>\n      <li>Rybomustyn (UA);</li>\n      <li>Symbenda (KR, SG);</li>\n      <li>Treakisym (JP);</li>\n      <li>Treanda (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aivado M, Schulte K, Henze L, et al, &ldquo;Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives,&rdquo; <i>Semin Oncol</i>, 2002, 29(4 Suppl 13):19-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/12170428/pubmed\" target=\"_blank\" id=\"12170428\">12170428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bendeka (bendamustine hydrochloride) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheson BD, Wendtner CM, Pieper A, et al, &ldquo;Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel,&rdquo; <i>Clin Lymphoma Myeloma Leuk</i>, 2010, 10(1):21-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20223726/pubmed\" target=\"_blank\" id=\"20223726\">20223726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>J Clin Oncol</i>. 2013. 31(1):104-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23109692/pubmed\" target=\"_blank\" id=\"23109692\">23109692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25829094\"></a>Darwish M, Bond M, Hellriegel E , Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. <i>Cancer Chemother Pharmacol</i>. 2015;75(6):1143-1154. doi: 10.1007/s00280-015-2727-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/25829094/pubmed\" target=\"_blank\" id=\"25829094\">25829094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dubbelman AC, Rosing H, Darwish M, et al, &ldquo;An Open-Label Phase I Pharmacokinetic Study of [<sup>14</sup>c] Bendamustine in Patients with Relapsed or Refractory Malignancy,&rdquo; <i>Blood</i>, 2011, 118(21):2746 [abstract 2746 from 2011 ASH Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer K, Cramer P, Busch R, et al, &ldquo;Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,&rdquo; <i>J Clin Oncol</i>, 2011, 29(26):3559-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21844497/pubmed\" target=\"_blank\" id=\"21844497\">21844497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer K, Cramer P, Busch R, et al, &ldquo;Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,&rdquo; <i>J Clin Oncol</i>, 2012, 30(26):3209-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22869884/pubmed\" target=\"_blank\" id=\"22869884\">22869884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24591201\"></a>Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i>. 2014;123(19):2944-2952.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/24591201/pubmed\" target=\"_blank\" id=\"24591201\">24591201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21810687\"></a>Fowler N, Kahl BS, Lee P, et al, &ldquo;Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,&rdquo; <i>J Clin Oncol</i>, 2011, 29(25):3389-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21810687/pubmed\" target=\"_blank\" id=\"21810687\">21810687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedberg JW, Cohen P, Chen L, et al, &ldquo;Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study,&rdquo; <i>J Clin Oncol</i>, 2008, 26(2):204-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/18182663/pubmed\" target=\"_blank\" id=\"18182663\">18182663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedberg JW, Vose JM, Kelly JL, et al, &ldquo;The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,&rdquo; <i>Blood</i>, 2011, 117(10):2807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21239695/pubmed\" target=\"_blank\" id=\"21239695\">21239695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iannitto E, Morabito F, Mancuso S, et al, &ldquo;Bendamustine With or Without Rituximab in the Treatment of Relapsed Chronic Lymphocytic Leukaemia: An Italian Retrospective Study,&rdquo; <i>Br J Haematol</i>, 2011, 153(3):351-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21371003/pubmed\" target=\"_blank\" id=\"21371003\">21371003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahl BS, Bartlett NL, Leonard JP, et al, &ldquo;Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study,&rdquo; <i>Cancer</i>, 2010, 116(1):106-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/19890959/pubmed\" target=\"_blank\" id=\"19890959\">19890959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knauf WU, Lissitchkov T, Aldaoud A, et al, &ldquo;Bendamustine Compared With Chlorambucil In Previously Untreated Patients With Chronic Lymphocytic Leukaemia: Updated Results of a Randomized Phase III Trial,&rdquo; <i>Br J Haematol</i>, 2012, 159(1):67-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22861163/pubmed\" target=\"_blank\" id=\"22861163\">22861163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knauf WU, Lissichkov T, Aldaoud A, et al, &ldquo;Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia (B-CLL),&rdquo; <i>J Clin Oncol</i>, 2009, 27(26):4378-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/19652068/pubmed\" target=\"_blank\" id=\"19652068\">19652068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16154860\"></a>Knop S, Straka C, Haen M, et al, &ldquo;The Efficacy and Toxicity of Bendamustine in Recurrent Multiple Myeloma After High-Dose Chemotherapy,&rdquo; <i>Haematologica</i>, 2005, 90(9):1287-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/16154860/pubmed\" target=\"_blank\" id=\"16154860\">16154860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22451423\"></a>Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. <i>Blood</i>. 2012;119(20):4608-4613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22451423/pubmed\" target=\"_blank\" id=\"22451423\">22451423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludwig H, Kasparu H, Leitgeb C, et al, Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. <i>Blood</i>. 2014;123(7):985-991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/24227817/pubmed\" target=\"_blank\" id=\"24227817\">24227817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michael M, Bruns I, B&ouml;lke E, et al, &ldquo;Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma,&rdquo; <i>Eur J Med Res</i>, 2010, 15(1):13-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20159666/pubmed\" target=\"_blank\" id=\"20159666\">20159666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23248254\"></a>Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>J Clin Oncol</i>. 2013;31(4):456-460.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23248254/pubmed\" target=\"_blank\" id=\"23248254\">23248254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23987821\"></a>Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, Sterchele JA. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. <i>Leuk Lymphoma</i>. 2014;55(6):1266-1273. doi: 10.3109/10428194.2013.836600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23987821/pubmed\" target=\"_blank\" id=\"23987821\">23987821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Owen JS, Melhem M, Passarell JA, et al, &ldquo;Bendamustine Pharmacokinetic Profile and Exposure-Response Relationships in Patients With Indolent Non-Hodgkin's Lymphoma,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2010, 66(6):1039-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20140617/pubmed\" target=\"_blank\" id=\"20140617\">20140617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ponisch W and Niederwieser D, &ldquo;Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives,&rdquo; <i>Semin Oncol</i>, 2002, 29(4 Suppl 13):23-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/12170429/pubmed\" target=\"_blank\" id=\"12170429\">12170429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson KS, Williams ME, van der Jagt RH, et al, &ldquo;Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2008, 26(27):4473-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/18626004/pubmed\" target=\"_blank\" id=\"18626004\">18626004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15908650\"></a>Rummel MJ, Al-Batran SE, Kim SZ, et al, &ldquo;Bendamustine Plus Rituximab is Effective and has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2005, 23(15):3383-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/15908650/pubmed\" target=\"_blank\" id=\"15908650\">15908650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23433739\"></a>Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <i>Lancet</i>. 2013. 381(9873):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23433739/pubmed\" target=\"_blank\" id=\"23433739\">23433739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulmeister L, &quot;Extravasation Management: Clinical Update,&quot; <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21255716/pubmed\" target=\"_blank\" id=\"21255716\">21255716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27345636\"></a>Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicenter, phase 3 trial. <i>Lancet Oncol</i>. 2016;17(8):1081-1093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/27345636/pubmed\" target=\"_blank\" id=\"27345636\">27345636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Update on bendamustine and CSTDs. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(5):2-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tapan U, May SK, Fiore J, et al, &ldquo;Reactivation of Hepatitis B Virus Following Bendamustine-Containing Chemotherapy in a Patient With Multiple Myeloma,&rdquo; <i>Leuk Lymphoma</i>, 2011, 52(5):916-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21306291/pubmed\" target=\"_blank\" id=\"21306291\">21306291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teichert J, Baumann F, Chao Q, et al, &ldquo;Characterization of Two Phase I Metabolites of Bendamustine in Human Liver Microsomes and in Cancer Patients Treated With Bendamustine Hydrochloride,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2007, 59(6):759-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/16957931/pubmed\" target=\"_blank\" id=\"16957931\">16957931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teichert J, Sohr R, Baumann F, et al, &ldquo;Synthesis and Characterization of Some New Phase II Metabolites of the Alkylator Bendamustine and Their Identification in Human Bile, Urine, and Plasma From Patients With Cholangiocarcinoma,&rdquo; <i>Drug Metab Dispos</i>, 2005, 33(7):984-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/15845750/pubmed\" target=\"_blank\" id=\"15845750\">15845750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teva US Specialty Medicines. Treanda medical information [written communication]. North Wales, PA: Teva Pharmaceuticals; February 11, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treanda (bendamustine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21454214\"></a>Treon SP, Hanzis C, Tripsas C, et al, &ldquo;Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstr&ouml;m's Macroglobulinemia,&rdquo; <i>Clin Lymphoma Myeloma Leuk</i>, 2011, 11(1):133-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21454214/pubmed\" target=\"_blank\" id=\"21454214\">21454214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 28, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T. Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9323 Version 179.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5957167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F15065726\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5957171\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5958743\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5957380\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5957381\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5957382\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20339757\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F5957403\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5957484\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5957169\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50085705\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5957404\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130899\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5957173\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475187\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5957165\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5957205\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5957180\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5957181\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5957266\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5957265\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F5957175\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5957176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5957179\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5957481\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5957479\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5957371\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321818\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875349\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9323|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bendamustine-patient-drug-information\" class=\"drug drug_patient\">Bendamustine: Patient drug information</a></li></ul></div></div>","javascript":null}